

Docket. No. \_\_\_\_\_

**DECLARATION (37 C.F.R. § 1.63) AND POWER OF ATTORNEY**

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**NOVEL COMPOUNDS**

the specification of which

- ☐ is attached hereto.
- ☐ was filed on \_\_\_\_\_ as Application No. \_\_\_\_\_ and was amended on \_\_\_\_\_.
- ☒ was filed on 15 December 2000 as PCT International Application No. PCT/SE00/02562 and was amended under PCT Article 19 on \_\_\_\_\_, if applicable.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 C.F.R. § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119, of any United States provisional applications or foreign application(s) for patent or inventor's certificate or of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed:

Application Serial No.	Country	Filing Date (Day/Month/Year)	Priority Claimed (Yes/No)
9904674-0	SE	20 December 1999	YES

Docket. No. \_\_\_\_\_

I hereby claim the benefit under Title 35, United States Code, Section 120, of any United States application(s) or PCT International Application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56, which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application  
Serial No.

Filing Date

Status (Patented,  
Pending, Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint William P. Atkins, Reg. No. 38,821; Jack S. Barufka, Reg. No. 37,087; W. Patrick Bengtsson, Reg. No. 32,456; Donald J. Bird, Reg. No. 25,323; Kendrew H. Colton, Reg. No. 30,368; Michael R. Dzwonczyk, Reg. No. 36,787; Lynn E. Eccleston, Reg. No. 35,861; G. Paul Edgell, Reg. No. 24,238; Jay M. Finkelstein, Reg. No. 21,082; Stephen C. Glazier, Reg. No. 31,361; Peter W. Gowdey, Reg. No. 25,872; Adam R. Hess, Reg. No. 41,835; David A. Jakopin, Reg. No. 32,995; Kevin E. Joyce, Reg. No. 20,508; Timothy J. Klima, Reg. No. 34,852; G. Lloyd Knight, Reg. No. 17,698; Paul N. Kokulis, Reg. No. 16,773; Dale S. Lazar, Reg. No. 28,872; Raymond F. Lippitt, Reg. No. 17,519; Carl G. Love, Reg. No. 18,781; Paul F. McQuade, Reg. No. 31,542; Ruth N. Morduch, Reg. No. 31,044; Mark G. Paulson, Reg. No. 30,793; Glenn J. Perry, Reg. No. 28,458; Michael A. Sanzo, Reg. No. 36,912; Paul L. Sharer, Reg. No. 36,004; George M. Sirilla, Reg. No. 18,221; Paul E. White, Jr., Reg. No. 32,011; Roger R. Wise, Reg. No. 31,204; Richard H. Zaitlen, Reg. No. 27,248, all registered to practice before the Patent and Trademark Office, as my attorneys with full power of substitution and revocation to prosecute this application and all divisions and continuations thereof and to transact all business in the Patent and Trademark Office connected therewith and request that all correspondence and telephone communications be directed to the following person(s) at the mailing address and telephone number hereafter given:

Name:	Michael A. Sanzo
Registration No.:	36,912
Address:	Pillsbury Winthrop LLP 1100 New York Avenue, N.W. Ninth Floor Washington, DC 20005-3918
Telephone No.:	(202) 861-3020

**Inventor's Signature** \_\_\_\_\_

**Date** By 27/2002

Full name of sole or first inventor: BROWN, William

Residence Address: St. Laurent, Canada

Citizenship: Canada

Post Office Address: AstraZeneca R&D Montreal, 7171 Frederick-Banting, St. Laurent,  
Quebec H4S 1Z9, Canada

**Inventor's Signature** \_\_\_\_\_

**Date** May 23<sup>rd</sup> 2002

Full name of second joint inventor: WALPOLE, Christopher

Residence Address: St. Laurent, Canada

Citizenship: United Kingdom

Post Office Address: AstraZeneca R&D Montreal, 7171 Frederick-Banting, St. Laurent,  
Quebec H4S 1Z9, Canada

**Inventor's Signature** \_\_\_\_\_


**Date** June 13 2002

Full name of third joint inventor: PLOBECK, Niklas

Residence Address: St. Laurent, Canada

Citizenship: Sweden

Post Office Address: AstraZeneca R&D Montreal, 7171 Frederick-Banting, St. Laurent,  
Quebec H4S 1Z9, Canada



MAY 06, 2003

PTAS

FITCH, EVEN, TABIN & FLANNERY  
MICHAEL A. SANZO  
1801 K STREET, N.W., SUITE 401L  
WASHINGTON, D.C. 20006-1201

Under Secretary of Commerce For Intellectual Property and  
Director of the United States Patent and Trademark Office  
Washington, DC 20231  
www.uspto.gov



\*102329591A\*

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 10/21/2002

REEL/FRAME: 013626/0358  
NUMBER OF PAGES: 5

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

BROWN, WILLIAM

DOC DATE: 05/27/2002

ASSIGNOR:

WALPOLE, CHRISTOPHER

DOC DATE: 05/23/2002

ASSIGNOR:

PLOBECK, NIKLAS

DOC DATE: 06/13/2002

ASSIGNEE:

ASTRAZENECA AB  
S-151 85 SODERTALJE, SWEDEN

SERIAL NUMBER: 10149981

PATENT NUMBER:

FILING DATE: 10/21/2002

ISSUE DATE:

RECEIVED

MAY - 9 2003

FETE D.C.

013626/0358 PAGE 2

MARY BENTON, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

---

01-07-2003



102329591

COVER SHEET

U.S. DEPARTMENT OF COMMERCE

ONLY

Patent and Trademark Office

To the Honorable Com

Record the attached original documents or copy thereof.

21 OCT 2002

## 1. Name of conveying party(ies):

William Brown, Christopher Walpole,  
Niklas PlobeckAdditional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

10/21/02

## 2. Name and address of receiving party(ies):

Name: AstraZeneca AB

Internal Address:

Street Address:

City/State/ZIP: S-151 85 Södertälje

SWEDEN

Additional name(s) & address(es)  
attached? ☐ Yes ☒ No

## 3. Nature of conveyance:

- ☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ Other

Execution Date: May 27, 2002, May 23, 2002 and June 13, 2002

## 4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

10/149,981

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No

## 5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Michael A. Sanzo

Internal Address:

Street Address: Fitch, Even, Tabin & Flannery  
1801 K Street, N.W.  
Suite 401L

City/State/ZIP: Washington, D.C. 20006-1201

## 6. Total number of applications and patents involved:

1

7. Total Fee (37 C.F.R. § 3.41) \$ 40.00

- ☐ Enclosed  
☒ Authorized to be charged to deposit account

## 8. Deposit account number:

06-1135 Under Order No. 7567/73249

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

## 9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Michael A. Sanzo  
Name of Person SigningMichael A. Sanzo  
SignatureOctober 20, 2002  
Date

Total number of pages including cover sheet, attachments, and document:

3

Mail documents to be recorded with required cover sheet information to:  
 Commissioner of Patents & Trademarks, Box Assignments  
 Washington, D.C. 20231

FORM6-03.WP5

7/28/2002 LLANDGRA 00000053 061135 10149981

FOLB001 40.00 CH

**Assignment to AstraZeneca AB**


**Title:** NOVEL COMPOUNDS  
**Inventors:** BROWN, William; WALPOLE, Christopher; PLOBECK, Niklas  
**PCT Appl. No:** PCT/SE00/02562  
**Intn'l Filing Date:** 15 December 2000  
**Execution Date of Application:**  
**Country of PCT Receiving Office:** Sweden

As a below-named inventor, I hereby declare that:

My post office address is as stated below under my signature and I am named as inventor of the ~~inventions or discoveries~~ (herein INVENTIONS) as described in the patent application (herein APPLICATION) identified above. In view of valuable consideration, receipt thereof is hereby acknowledged, I do hereby assign and transfer unto AstraZeneca AB, a corporation of Sweden having a place of business at Södertälje, its successors and assigns, my entire interest in and the full and exclusive right to the INVENTIONS, the APPLICATION and all related applications (including all divisions, reissues, continuations, and extensions thereof) and all counterparts in other countries, and any and all Letters Patent (and certificates of invention or similar certificates) (herein PATENTS) which may be granted based upon the INVENTIONS or the APPLICATION or related applications or counterparts in other countries; said transfer and assignment being applicable throughout the world. I hereby authorize and request officials of patent offices in any and all countries of the world to issue any and all of the PATENTS, when granted, to AstraZeneca AB, its successors and assigns, as the assignee of my entire right, title, and interest in and to the same. I agree that I will communicate to AstraZeneca AB, or its representatives, any facts known to me respecting the invention; testify in any legal proceedings; sign all lawful papers; execute all divisional, continuation, substitution, renewal, and reissue applications; execute all necessary assignment papers to cause any and all of the PATENTS to be issued to AstraZeneca AB; make all rightful oaths; and generally do everything possible to aid AstraZeneca AB, its successors and assigns, to obtain and enforce proper protection for the INVENTION in any and all countries throughout the world.




FULL NAME OF FIRST/SOLE INVENTOR: BROWN, William

Signature of Inventor: 

Address: AstraZeneca R&D Montreal, 7171 Frederick-Banting, St. Laurent, Quebec H4S 1Z9, Canada

Date: May 27 2002


FULL NAME OF SECOND/JOINT INVENTOR: WALPOLE, Christopher

Signature of Inventor: 

Address: AstraZeneca R&D Montreal, 7171 Frederick-Banting, St. Laurent, Quebec H4S 1Z9, Canada

Date: May 23 2002

FULL NAME OF THIRD/JOINT INVENTOR: PLOBECK, Niklas

Signature of Inventor: 

Address: AstraZeneca R&D Montreal, 7171 Frederick-Banting, St. Laurent, Quebec H4S 1Z9, Canada

Date: June 13 2002